Stocks and Investing Stocks and Investing
Fri, December 3, 2021
Thu, December 2, 2021

Brian Abrahams Maintained (VRTX) at Buy with Increased Target to $265 on, Dec 2nd, 2021


Published on 2024-10-27 18:51:09 - WOPRAI, Brian Abrahams
  Print publication without navigation


Brian Abrahams of RBC Capital, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $250 to $265 on, Dec 2nd, 2021.

Brian has made no other calls on VRTX in the last 4 months.



There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 3 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Do Kim of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $218 on, Friday, November 19th, 2021
  • Evan Seigerman of "BMO Capital" Initiated at Hold and Held Target at $202 on, Friday, November 19th, 2021
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $213 on, Thursday, September 9th, 2021


These are the ratings of the 3 analyists that currently disagree with Brian


  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $286 on, Wednesday, December 1st, 2021
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $341 on, Wednesday, December 1st, 2021
  • Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell and Held Target at $202 on, Tuesday, September 7th, 2021

Contributing Sources